umbilical cord blood-derived mesenchymal stem cell therapy (Asia Stem Cell Regenerative Pharmaceutical)

N/A

Report date: 2025/01/26 16:42:27

Base Information

Drug Nameumbilical cord blood-derived mesenchymal stem cell therapy (Asia Stem Cell Regenerative Pharmaceutical)
Drug Alias Nameumbilical cord blood-derived mesenchymal stem cell therapy (Asia Stem Cell Regenerative Pharmaceutical)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsDecompensated Liver CirrhosisRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAsia Stem Cell Regenerative Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAsia Stem Cell Regenerative Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDecompensated Liver CirrhosisRespiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A